ARMATA PHARMACEUTICALS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2020 - Q4(Apr 20 · May 20 · Jun 20)
Total Assets
$77M
↓-11.1% -$10Mvs FY2024
Total Liabilities
$295M
↑+119.8% +$161Mvs FY2024
Cash
$9M
↓-6.5% -$603Kvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $77M | $86M |
| Current Assets | $11M | $11M |
| Cash | $9M | $9M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $2M | $2M |
| Non-Current Assets | $66M | $75M |
| PPE | $12M | $13M |
| Goodwill | $3M | $3M |
| Intangibles | $10M | $10M |
| Investments | $0 | $0 |
| Other Non-Current | $40M | $48M |
| Total Liab+Eq | $77M | $86M |
| Current Liab. | $9M | $48M |
| Accounts Payable | $921K | $766K |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $8M | $47M |
| Non-Current Liab. | $287M | $86M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $287M | $86M |
| Equity | $-219M | $-48M |
| Retained Earnings | $502M | $328M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · ARMP · Comparing FY2025 vs FY2024